SCHEMBL26323232

SCHEMBL26323232

CCCCOC(=O)Oc1cccc2[nH]cc(CCN(C)C)c12

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.63
HTR6 P50406 2/20 0.59
HTR1A P08908 6/20 0.58
HTR2C P28335 4/20 0.58
HTR2B P41595 4/20 0.58
HTR1B P28222 5/20 0.52
HTR1D P28221 5/20 0.52
DRD1 P21728 1/20 0.52
HTR1E P28566 1/20 0.52
ADORA2A P29274 1/20 0.52
ADORA2B P29275 1/20 0.52
HTR7 P34969 1/20 0.52
DRD3 P35462 1/20 0.52
HTR5A P47898 1/20 0.52
HTR1F P30939 1/20 0.48
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
ELANE P08246 1/20 0.46
SLC6A4 P31645 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26646464 0.97 HTR2A (0.65) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL26307597 0.96 HTR2A (0.66) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL25790561 0.95 HTR6 (0.62) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL31404490 0.94 HTR6 (0.61) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL26323233 0.94 HTR6 (0.61) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL31404488 0.90 HTR6 (0.62) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL25074574 0.89 HTR6 (0.64) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL30637142 0.89 HTR6 (0.64) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL31024345 0.89 HTR6 (0.56) HTR2AHTR6HTR1AHTR2CHTR2B
SCHEMBL26307748 0.89 HTR6 (0.56) HTR2AHTR6HTR1AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295086-A1 NOVEL PSILOCIN DERIVATIVES HAVING PRODRUG PROPERTIES HERCULES CAPITAL, INC. 2023-09-21 US disclosed
US-20230295086-A1 NOVEL PSILOCIN DERIVATIVES HAVING PRODRUG PROPERTIES HERCULES CAPITAL, INC. 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295086-A1 NOVEL PSILOCIN DERIVATIVES HAVING PRODRUG PROPERTIES HTR2A, HTR2C, HTR5A HTR2A 1/4885HTR6 8/4885HTR1A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.